CClinicalTrials.gg
CompletedNCT05675956Updated Mar 28, 2024

Acute Nerve Stimulation For Enhancing Human and Cognitive Performance

An interventional study of Experimental group with 100% intensity setting on Apollo Neuro device and Active Comparator group with 10% intensity setting on the Apollo Neuro device in Concussion, Mild, Autonomic Nervous System and Cognitive, sponsored by University of South Carolina. Completed at 1 site in United States. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-28.

Sponsored by University of South Carolina · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

The goal of this clinical trial is to test a wearable device's effect on performance in tactical populations with a history of concussion. The main question it aims to answer is the effectiveness of the device on modulate physiological and cognitive function.

The physiological function will be derived from metrics of heart rate variability and blood-based biomarkers, whilst human performance will be evaluated using tasks that assess cognitive domains of executive function, reaction time, and memory.

Read the detailed description

This study will compare the effects of two different settings of the ApolloNeuro™ Device on physiological and cognitive function. This device is worn on the wrist and produces silent low-frequency waves that feel like slight vibrations. The purpose of the device is to modulate autonomic nervous system function. There will be a total of 3 laboratory visits, each lasting approximately 3.5 hours, separated by 3-5 days to allow for physiological recovery. The first visit will include an exercise test to determine participants maximum exercise capacity and to familiarize participants with a battery of psycho-motor cognitive tasks. The remaining two visits will be experimental days differentiated by a low or high-intensity setting of the ApolloNeuro™ Device. The experimental order will be randomized. This means that neither the participant nor the research team will know which condition has been assigned. On the experimental days, participants will have blood drawn from their arm and complete psycho-motor cognitive measures before and after a 20-minute interval running workout. This study will help to acquire knowledge of how wearable devices may improve physiological and cognitive function.

02

Conditions studied

  • Concussion, Mild
  • Autonomic Nervous System
  • Cognitive

Browse trials for

03

In context

Brain Concussion

530 studies on the registry are indexed under Brain Concussion; 151 are open to participants now.

This study's enrollment of 35 is below the median of 64 across 364 interventional studies indexed under Brain Concussion.

Browse Brain Concussion studies →

Lead sponsor

University of South Carolina is the lead sponsor of 191 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Participant is between 18-30 BMI.
  • Participant needs to be either an ROTC member, currently employed military or law enforcement officer or are a military veteran or retired law enforcement officer who has completed service in the past 18 months.
  • Participant has provided written and dated informed consent.
  • Participant is in good health and able to participate in high-intensity exercise.
  • Participant have been clinically diagnosed with a concussion at least 3 months prior to screening and is asymptomatic.
  • Participant is willing to maintain their current dietary supplement usage through the duration of the study. If the participant began taking another supplement within the past month, the participant will be asked to discontinue supplement use followed by a 2-week washout prior to participation.

Exclusion criteria

Exclusion Criteria:

  • Participant with any musculoskeletal injuries that would prevent exercising.
  • Participant with any metabolic disorder including known electrolyte abnormalities, diabetes, thyroid disease, adrenal disease or hypogonadism.
  • Participant with a history of hepatorenal, musculoskeletal, or autoimmune disease.
  • Participant with a personal history of heart disease, cardiovascular conditions, high blood pressure (systolic >140 mm Hg \& diastolic >90 mm Hg), psychiatric disorders, neurological disorders, developmental disorders, cancer, benign prostate hypertrophy, gastric ulcer, reflux disease, or any other medical condition (i.e. visual/auditory) deemed exclusionary by the medical staff.
  • Participant currently taking medication that affects the ANS such as thyroid, hyperlipidemic, hypoglycemic, anti-hypertensive, anticoagulant, or psychotropic medications, or antihistamines.
  • Participant who is pregnant or lactating.
  • Participant with any of the following concussion characteristics; history of >3 concussions, loss of consciousness (>5 minutes), cause of injury related to violence e.g. physical altercations.
  • Participants with a history of moderate to severe TBI.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    High Intensity

    The device will be set to 100% intensity for this group.

    Device: Experimental group with 100% intensity setting on Apollo Neuro device

  • Active comparator
    Low Intensity

    The device will be set to 10% intensity in this group

    Device: Active Comparator group with 10% intensity setting on the Apollo Neuro device

Interventions

  • DeviceExperimental group with 100% intensity setting on Apollo Neuro device

    The group will have the device set to 100% intensity at one of their two experimental visits.

  • DeviceActive Comparator group with 10% intensity setting on the Apollo Neuro device

    The group will have the device set to 10% intensity at one of their two experimental visits.

06

What researchers measure

Primary outcomes

  1. Changes in dopamine

    To determine if the device has an impact on dopamine levels

    Time frame: Will be assessed at visits 2 and 3 prior exercise (minute 0) , immediately following exercise (about 1.5 hour), and immediately post one hour recovery (at about hour 3) on experimental visits.

  2. Changes in epinephrine

    To determine if the device has an impact on epinephrine levels

    Time frame: Will be assessed at visits 2 and 3 prior exercise (minute 0) , immediately following exercise (about 1.5 hour), and immediately post one hour recovery (at about hour 3) on experimental visits.

  3. Changes in norepinephrine

    To determine if the device has an impact on norepinephrine levels

    Time frame: Will be assessed at visits 2 and 3 prior exercise (minute 0) , immediately following exercise (about 1.5 hour), and immediately post one hour recovery (at about hour 3) on experimental visits.

  4. Changes in cortisol

    To determine if the device has an impact on cortisol levels

    Time frame: Will be assessed at visits 2 and 3 prior exercise (minute 0) , immediately following exercise (about 1.5 hour), and immediately post one hour recovery (at about hour 3) on experimental visits.

  5. Changes in arousal

    To determine if the device has an impact on arousal levels measured by the "Felt Arousal Scale". The minimum score is 1 and maximum score is 6. These measures are not indicative of better or worse outcomes.

    Time frame: Will be assessed at visits 2 and 3 prior exercise (minute 0) on experimental visits.

  6. Sleep Quality

    Index of sleep quality using the Neurology Quality of Life (Neuro-QOL) sleep subscale.

    Time frame: Will be assessed at visits 2 and 3 prior exercise (minute 0) on experimental visits.

  7. Changes in fatigue

    To determine if the device has an impact on fatigue levels measured by the "Fatigue Scale". The minimum score is 1 and maximum score is 5. These measures are not indicative of better or worse outcomes.

    Time frame: Will be assessed prior exercise (minute 0), immediately after the bout of exercise (about hour 1.5), post cognitive testing (about 2 hour), and immediately post one hour recovery (about hour 3) on experimental visits.

  8. Changes in Marksmanship Accuracy

    Simulated marksmanship using optical targetry

    Time frame: Will be assessed prior exercise (minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  9. Changes in Marksmanship Reaction Time

    Simulated marksmanship using optical targetry

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  10. Changes in cognitive flexibility by local switch cost RT (Switch Task)

    To determine if the device has an impact on cognitive flexibility by measuring local switch cost RT within the heterogenous condition when switching rule sets represented as the additional time to respond to switch relative to repeat trials.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  11. Changes in cognitive flexibility by local switch cost ACC (Switch Task)

    To determine if the device has an impact on cognitive flexibility by measuring local switch cost ACC within the heterogenous condition when switching rule sets represented as the difference between error rates for switch relative to repeat trials.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  12. Changes in cognitive flexibility by local switch cost IES (Switch Task)

    To determine if the device has an impact on cognitive flexibility by measuring local switch cost inverse efficiency scores (IES) represented as dividing RTs by 1 minus the percentage of errors (i.e., percentage of correct responses).

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  13. Changes in global executive function by global cost RT (Switch Task)

    To determine if the device has an impact on global executive function by measuring global cost RT represented as the difference between the time required to respond between the heterogeneous and homogeneous conditions.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  14. Changes in global executive function by global cost ACC (Switch Task)

    To determine if the device has an impact on global executive function by measuring global cost ACC represented as the difference between error rates between homogeneous and heterogeneous conditions.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  15. Changes in global executive function by global cost IES (Switch Task)

    To determine if the device has an impact on global executive function by measuring global cost IES.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  16. Changes in working memory by mixing cost RT (Switch Task)

    To determine if the device has an impact on working memory by measuring mixing cost RT represented as the additional time required to respond between the repeat trials in the heterogenous condition relative to the trials in the homogeneous condition.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  17. Changes in working memory by mixing cost ACC (Switch Task)

    To determine if the device has an impact on working memory by measuring mixing cost ACC represented as the difference in error rates on repeat trials in the heterogenous condition relative to the trials in the homogeneous condition.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  18. Changes in working memory by mixing cost IES (Switch Task)

    To determine if the device has an impact on working memory by measuring mixing cost IES.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  19. Changes in attention (Switch Task)

    To determine if the device has an impact on attention measured by the omission errors when an individual fails to respond to a color-switch task trial, and omission error runs when an individual fails to respond to multiple successive trials.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  20. Changes in Inhibitory Control (Switch Task)

    To determine if the device has an impact on inhibitory control measured by the commission errors when an individual fails to respond correctly to a color-switch task trial, and commission error runs when an individual fails to respond correctly to multiple successive trials.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  21. Changes in attention and cognitive control by ACC (Switch Task)

    To determine if the device has an impact on attention and cognitive control by measuring heterogeneous condition ACC.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  22. Changes in attention and cognitive control by RT (Switch Task)

    To determine if the device has an impact on attention and cognitive control by measuring heterogeneous condition RT.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  23. Changes in attention and cognitive control by IES (Switch Task)

    To determine if the device has an impact on attention and cognitive control by measuring heterogeneous condition IES.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  24. Changes in Inhibitory Control (Go/No go)

    To determine if the device has an impact on inhibitory control by measuring reaction time to Go targets (hits). To determine if the device has an impact on inhibitory control by measuring errors of commission representing incorrect responses to the target NoGo (false alarm).

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  25. Changes in Attention (Go/No go)

    To determine if the device has an impact on attention by measuring errors of omission to the target Go (misses).

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  26. Changes in Autonomic Nervous System Function (ANS) by linear metrics

    To determine if the device has an impact on ANS function by measuring heart rate variability represented by linear (RMSSD, SDNN, CVNN) time domain metrics.

    Time frame: This will be continuously assessed throughout the entirety of experimental visits 2 and 3 (minute 0 to about 3 hours)..

  27. Changes in Autonomic Nervous System Function (ANS) by nonlinear metrics

    To determine if the device has an impact on ANS function by measuring heart rate variability represented by nonlinear (ApSaEn) time domain metric.

    Time frame: This will be continuously assessed throughout the entirety of experimental visits 2 and 3 (minute 0 to about 3 hours)..

  28. Changes in Autonomic Nervous System Function (ANS) by frequency domain metrics

    To determine if the device has an impact on ANS function by measuring heart rate variability represented by frequency domain (HF, LF, Coherence Ratio) metrics.

    Time frame: This will be continuously assessed throughout the entirety of experimental visits 2 and 3 (minute 0 to about 3 hours)..

  29. Changes in Inhibitory Control by accuracy scores (Flanker Task)

    To determine if the device has an impact on inhibitory control measured by the accuracy scores (% of correct answers) for compatible-congruent, incompatible-congruent, compatible-incongruent, and incompatible-incongruent Flanker Task trials.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  30. Changes in Inhibitory Control by average response time (Flanker Task)

    To determine if the device has an impact on inhibitory control measured by the average response time to incongruent flanker task trials irrespective of compatible or incompatible rule sets.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  31. Changes in Inhibitory Control by commission errors (Flanker Task)

    To determine if the device has an impact on inhibitory control measured by the commission errors when an individual fails to respond correctly to a flanker task trial, and commission error runs when an individual fails to respond correctly to multiple successive trials.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  32. Changes in Attention by accuracy (Flanker Task)

    To determine if the device has an impact on attention measured by the accuracy scores for congruent-compatible Flanker task trials.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  33. Changes in Attention by average response time (Flanker Task)

    To determine if the device has an impact on attention measured by the overall average response time (milliseconds) to compatible and incompatible Flanker task trails irrespective of trial congruency.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  34. Changes in Attention by omission errors (Flanker Task)

    To determine if the device has an impact on attention measured by the omission errors when an individual fails to respond to a flanker task trial, and omission error runs when an individual fails to respond to multiple successive trials.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  35. Changes in Cognitive flexibility by accuracy (Flanker Task)

    To determine if the device has an impact on cognitive flexibility by the accuracy scores for incongruent-incompatible Flanker task trials.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  36. Changes in Cognitive flexibility by average response time (Flanker Task)

    To determine if the device has an impact on cognitive flexibility measured by the average response time to incongruent-incompatible flanker task trials.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  37. Changes in Cognitive control by post-error accuracy (Flanker Task)

    To determine if the device has an impact on cognitive control measured by post-error accuracy on Flanker task trials following an error.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  38. Changes in Cognitive control by sequential congruency effect (Flanker Task)

    To determine changes in cognitive control measured by sequential congruency effect when lower interference occurs following an incongruent relative to a congruent flanker task trial reflecting a consciously controlled narrowing of attention to the central target.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  39. Changes in Cognitive control by inverse efficiency (Flanker Task)

    To determine if the device has an impact on cognitive control measured by inverse efficiency a metric of a speed-accuracy trade-off for Flanker task trials.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  40. Changes in Attentional Inhibition (Flanker Task)

    To determine if the device has an impact on attentional inhibition measured by congruency interference representing the costs associated with the interference demands associated with incongruent vs congruent flanker task trials.

    Time frame: Will be assessed prior exercise (about minute 30) and immediately following the bout of exercise (about hour 1.5) on experimental visits.

  41. Changes in verbal learning (HVLT)

    To determine if the device has an impact on verbal learning by measuring total recall score via combining the word recall score from the three trials.

    Time frame: Will be assessed prior exercise (about minute 30), immediately following the bout of exercise (about 1.5 hours), and immediately post one hour recovery (about hour 3) on experimental visits.

  42. Changes in memory recall (HVLT)

    To determine if the device has an impact on memory by measuring delayed recall via the delayed recall score.

    Time frame: Will be assessed prior exercise (about minute 30), immediately following the bout of exercise (about 1.5 hours), and immediately post one hour recovery (about hour 3) on experimental visits.

  43. Changes in retention (HVLT)

    To determine if the device has an impact on memory by measuring retention via dividing the delayed recall trial by the score obtained on the trial prior exercise.

    Time frame: Will be assessed prior exercise (about minute 30), immediately following the bout of exercise (about 1.5 hours), and immediately post one hour recovery (about hour 3) on experimental visits.

  44. Changes in memory retention (HVLT)

    To determine if the device has an impact on memory by measuring retention via calculating a retention discrimination index by subtracting the total number of false positives from the total number of true positives.

    Time frame: Immediately post one hour recovery (hour 3) on experimental visits.

07

Study locations

1 site
  • University of South Carolina Sport Science Lab
    Columbia, South Carolina 29208, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05675956
Lead sponsor
University of South Carolina
Responsible party
Shawn M. Arent (Professor, University of South Carolina) — Principal investigator
First posted
Jan 9, 2023
Start date
Jan 15, 2023
Primary completion
Mar 27, 2024
Completion
Mar 27, 2024
Last update
Mar 28, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion